Advances in Immunotherapy of Multiple Myeloma: From the Discovery of Tumor-Associated Antigens to Clinical Trials

REFERENCES

• Myeloma Facts & Statistics. www.leukemia-lymphoma.org. Surveillance, Epidemiology and End Results (SEER), Cancer Statistics Review 1975–2003, National Cancer Institute, 2006.
   Google Scholar
• R. Bataille and J.L. Harousseau, Multiple myeloma, N. Engl. J. Med., 336(23): 1657–1664, 1997.
   PubMed Web of Science ®Google Scholar
• C. Pellat-Deceunynck, M.P. Mellerin, N. Labarriere, G. Jego, A. Moreau-Aubry, J.L. Harousseau, F. Jotereau, and R. Bataille, The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells, Eur. J. Immunol., 30(3): 803–809, 2000.
   PubMed Web of Science ®Google Scholar
• W. Matsui, C.A. Huff, Q. Wang, M.T. Malehorn, J. Barber, Y. Tanhehco, B.D. Smith, C.I. Civin, and R.J. Jones, Characterization of clonogenic multiple myeloma cells, Blood, 103(6): 2332–2336, 2004.
   PubMed Web of Science ®Google Scholar
• A.A. Jungbluth, S. Ely, M. DiLiberto, R. Niesvizky, B. Williamson, D. Frosina, Y.T. Chen, N. Bhardwaj, S. Chen-Kiang, L.J. Old, and H.J. Cho, The cancer testis antigens CT7 (MAGE-C1) and MAGEA3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation, Blood, 106(1): 167–174, 2005.
   PubMedGoogle Scholar
• P.R. Greipp, J. San Miguel, B.G. Durie, J.J. Crowley, B. Barlogie, J. Blade, M. Boccadoro, J.A. Child, H. Avet-Loiseau, R.A. Kyle, J.J. Lahuerta, H. Ludwig, G. Morgan, R. Powels, K. Shimizu, C. Shustik, P. Sonneveld, P. Tosi, I. Turesson, and J. Westin, International staging system for multiple myeloma, J. Clin. Oncol., 23(15): 3412–3420, 2005.
   PubMed Web of Science ®Google Scholar
• C.R. Parish, Cancer immunotherapy: The past, the present and the future, Immunol. Cell. Biol., 81(2): 106–113, 2003.
   PubMed Web of Science ®Google Scholar
• C.J.M. Melief and W.M. Kast, T cell immunotherapy of cancer, Res. Immunol., 142(5–6):425–429, 1991.
   Google Scholar
• C.J.M. Melief and W.M. Kast, Lessons from T cell responses to virus-induced tumors for cancer eradication in general, Cancer Surv., 13: 81–99, 1992.
   Google Scholar
• M.P. Velders, H. Schreiber, and W.M. Kast, Active immunization against cancer cells: Impediments and advances, Semin. Oncol., 25(6): 697–706, 1998.
   Google Scholar
• J.A. Brinkman, S.C. Fausch, J.S. Weber, and W.M. Kast, Peptide-based vaccine for cancer immunotherapy, Expert Opin. Biol. Ther., 4(2): 181–198, 2004.
   PubMed Web of Science ®Google Scholar
• F.M. Burnet, Immunological aspects of malignant disease, Lancet, 1(7501): 1171–1174, 1967.
   PubMed Web of Science ®Google Scholar
• J.D. Lewis, B.D. Reilly, and R.K. Bright, Tumor-associated antigens: From discovery to immunity, Int. Rev. Immunol., 22(2): 81–111, 2003.
   Web of Science ®Google Scholar
• P. Van der Bruggen, C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science, 254(5038): 1643–1647, 1991.
   PubMed Web of Science ®Google Scholar
• S.A. Rosenberg, Principles and practice of the biologic therapy of cancer. Philadelphia: Lippincott, 2000.
   Google Scholar
• K.C. Parker, M. Shields, M. DiBrino, A. Brooks, and J.E. Coligan, Peptide binding to MHC class I molecules: Implications for antigenic peptide prediction, Immunol. Res., 14(1): 34–57, 1995.
   Google Scholar
• J. D'Amaro, J.G.A. Houbiers, J.W. Drijfhout, R.M.P. Brandt, R. Schipper, J.N. Bouwes Bavinck, C.J.M. Melief, and W.M. Kast, A computer program for predicting possible CTL epitopes based on MHC class I peptide binding motives, Hum. Immunol., 43(1): 13–18, 1995.
   Google Scholar
• B. Peters, H.H. Bui, S. Frankild, M. Nielson, C. Lundegaard, E. Kostem, D. Basch, K. Lamberth, M. Harndahl, W. Fleri, S.S. Wilson, J. Sidney, O. Lund, S. Buus, and A. Sette, A community resource benchmarking predictions of peptide binding to MHC-I molecules, PLoS Comput. Biol., 2(6): e65, 2006.
   PubMed Web of Science ®Google Scholar
• G. Van Bleek and S. Nathenson, Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule, Nature, 348(6298): 213–216, 1990.
   Google Scholar
• P. Liang and A.B. Pardee, Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction, Science, 257(5072): 967–971, 1992.
   PubMed Web of Science ®Google Scholar
• F. Grizzi and M. Chiriva-Internati, The complexity of anatomical systems, Theor. Biol. Med. Model, 2: 26–34, 2005.
   PubMed Web of Science ®Google Scholar
• M. Chiriva-Internati, F. Grizzi, R.K. Bright, and W. Martin Kast, Cancer immunotherapy: Avoiding the road to perdition, J. Transl. Med., 2(1): 26–29, 2004.
   Google Scholar
• M.J. Scanlan, A.O. Gure, A.A. Jungbluth, L.J. Old, and Y.T. Chen, Cancer/testis antigens: An expanding family of targets for cancer immunotherapy, Immun. Rev., 188: 22–32, 2002.
   PubMed Web of Science ®Google Scholar
• M.J. Scanlan, A.J.G. Simpson, and L.J. Old, The cancer/testis genes: Review, standardization, and commentary, Cancer Immunity, 4: 1–15, 2004.
   PubMedGoogle Scholar
• L. Houet and H. Veelken, Active immunotherapy in multiple Myeloma, Eur. J. Cancer, 42(11): 1653–1660, 2006.
   PubMed Web of Science ®Google Scholar
• S.H. Lim, Z. Wang, M. Chiriva Internati, and Y. Xue, Sperm protein 17 is a novel cancer testis antigen in multiple myeloma, Blood, 97(5): 1508–1510, 2001.
   PubMed Web of Science ®Google Scholar
• M. Chiriva Internati, Z. Wang, E. Salati, K. Bumm, B. Barlogie, and S.H. Lim, Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma, Blood, 100(3): 961–965, 2002.
   Google Scholar
• Z. Wang, Y. Zhang, A. Mandal, J. Zhang, F.J. Giles, J.C. Herr, and S.H. Lim, The spermatozoa protein SLLP1 is a novel cancer testis antigen in hematological malignancies, Clin. Cancer Res., 10(19): 6544–6550, 2004.
   PubMed Web of Science ®Google Scholar
• B.J. Taylor, T. Reiman, J.A. Pittman, J.J. Keats, D.R. de Bruijn, M.J. Mant, A.R. Blech, and L.M. Pilarski, SSX cancer testis antigens are expressed in most multiple myeloma patients, J. Immunother, 28(6): 564–575, 2005.
   Google Scholar
• Z. Wang, J. Zhang, Y. Zhang, and S.H. Lim, Span-Xb expression in myeloma cells is dependent on promoter hypomethylation and can be upregulated pharmacologically, Int. J. Cancer, 118(6): 1436–1444, 2005.
   Google Scholar
• Z. Wang, Y. Zhang, H. Liu, E. Salati, M. Chiriva-Internati, and S.H. Lim, Gene expression and immunologic consequence of Span-Xb in myeloma and other hematologic malignancies, Blood, 101(3): 955–960, 2003.
   Google Scholar
• J. Epstein and S. Yaccoby, The SCID-hu myeloma model. Methods Mol. Med., 113: 183–190, 2005.
   Google Scholar
• A.R. Cattan and E. Douglas, The C.B. 17 SCID mouse strain as a model for human disseminated leukemia and myeloma in vivo, Leuk. Res., 18(7): 513, 1994.
   Google Scholar
• A.W. Tong, Y.W. Huang, B.Q. Zhang, G. Netto, E.S. Vitetta, and M.J. Stone, Heterotransplantation of human multiple myeloma cells in severe combined immunodeficiency (SCID) mice, Anticancer Res., 13(3): 593–597, 1993.
   Google Scholar
• W.T. Bellamy, A. Odeleye, P. Finely, B. Huizenga, W.S. Dalton, R.S. Weinstein, E.M. Hersh, and T.M. Grogan, An in vivo model of human multi drug-resistant multiple myeloma in SCID mice, Am. J. Pathol., 142(3): 691–698, 1993.
   Google Scholar
• Y.W. Huang, J.A. Richardson, A.W. Tong, B.Q. Zhang, M.J. Stone, and E.S. Vitetta, Disseminated growth of human multiple myeloma cell line in mice with severe combined immunodeficiency disease, Cancer Res., 53(6): 1392–1396, 1993.
   Google Scholar
• H. Suzuki, K. Yasukawa, T. Saito, R. Goitsuka, A. Hasegawa, Y. Ohsugi, T. Taga, and T. Kishimoto, Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo, Eur. J. Immunol., 22: 1989–1993, 1992.
   PubMed Web of Science ®Google Scholar
• Y.W. Huang, J.A. Richardson, and E.S. Vitetta, Anti CD-54 (Icam-1) has antitumor activity in scid mice with human myeloma cells, Cancer Res., 55(3): 610–616, 1995.
   Google Scholar
• W.T. Bellamy, P. Mendibles, P. Bontje, F. Thompson, L. Richter, R.S. Weinstein, and T.M. Grogan, Development of an orthotopic SCID mouse-human tumor xenograft model displaying the multidrug- resistant phenotype, Cancer Chemother Pharmacol, 37(4): 305–316, 1996.
   Google Scholar
• S. Yaccoby, B. Barlogie, and J. Epstein, Primary myeloma cells growing in SCID-hu mice: A model for studying the biology and treatment of myeloma and its manifestations, Blood, 92(8): 2908–2913, 1998.
   PubMed Web of Science ®Google Scholar
• I. Vlodavsky, O. Goldsmith, and E. Zcharia, Mammalian heparanase: Involvement in cancer metastasis, angiogenesis and normal development, Semin Cancer Biol., 12(2): 121–129, 2002.
   PubMed Web of Science ®Google Scholar
• J.B. Maxhimer, R.M. Quiros, R. Stewart, K. Dowlatshahi, P. Gattuso, M. Fan, R.A. Prinz, and X. Xu, Heparanase-1 expression is associated with the metastatic potential of breast cancer, Surgery, 132(2): 326–333, 2002.
   Google Scholar
• Y. Friedman, I. Vlodavsky, H. Aingorm, A. Aviv, T. Peretetz, I. Pecker, and O. Pappo, Expression of heparanase in normal, dysplastic and neoplastic human colonic mucosa and stroma: Evidence for its role in colonic tumorigenesis, Am. J. Pathol., 157(4): 1167–1175, 2000.
   Google Scholar
• S. Ginath, J. Menczer, Y. Friedmann, H. Aingorn, A. Aviv, K. Tajima, A. Dantes, M. Glezerman, I. Vlodavsky, and A. Amsterdam, Expression of heparanase, Mdm2 and erbB2 in ovarian cancer, Int. J. Oncol., 18(6): 1133–1144, 2001.
   Google Scholar
• K. Gohji, M. Okamoto, S. Kitazawa, M. Toyoshima, J. Dong, Y. Katsuoka, and M. Nakajima, Heparanase protein and gene expression in bladder cancer, J. Urol., 166(4): 1286–1290, 2001.
   Google Scholar
• A. Koliopanos, H. Friess, J. Kleeff, X. Shi, Q. Liao, I. Pecker, I. Vlodavsky, A. Zimmermann, and M.W. Buchler, Heparanase expression in primary and metastatic pancreatic cancer, Cancer Res., 61(12): 4655–4659, 2001.
   PubMed Web of Science ®Google Scholar
• M. Bitan, A. Polliack, G. Zecchina, A. Nagler, Y. Friedmann, L. Nadav, V. Deutsch, I. Pecker, A. Eldor, I. Vlodavsky, and B.Z. Katz, Heparanase expression in human leukemias is restricted to acute myeloid leukemias, Exp. Hematol., 30(1): 34–41, 2002.
   Google Scholar
• T. Kelly, H.Q. Miao, Y. Yang, E. Navarro, P. Kussie, Y. Huang, V. MacLeod, J. Casciano, L. Joseph, F. Zhan, M. Zangari, B. Barlogie, J. Shaughnessy, and R.D. Sanderson, High heparanase activity in multiple myeloma is associated with elevated microvessel density, Cancer Res., 63(24): 8749–8756, 2003.
   PubMed Web of Science ®Google Scholar
• Y. Yang, V. Mcleod, M. Bendre, Y. Huang, M.A. Theus, H.-Q. Miao, P. Kussie, S. Yaccoby, J. Epstein, J.L. Suva, T. Kelly, and R.D. Sanderson, Heparanase promotes the spontaneous metastasis of myeloma cell to bones, Blood, 105(3): 1303–1309, 2005.
   Google Scholar
• G.R. Mundy, B. Boyce, D. Hughes, K. Wright, L. Bonewald, and S. Dallas, The effects of cytochines and growth factors on osteoblastic cells, Bone, 17(2 suppl.): 71S–75S, 1995.
   Google Scholar
• S.C. Manolagas, Birth and death of bone cells: Basic regulatory mechanisms and implications for the patogenesis and treatment of osteoporosis, Endocr. Rev., 21(2): 115–137, 2000.
   PubMed Web of Science ®Google Scholar
• R.S. Weinstein and S.C. Manolagas, Apoptosis and osteoporosis, Am. J. Med., 108(2): 153–164, 2000.
   PubMed Web of Science ®Google Scholar
• R. Bataille, D. Chappard, C. Marcelli, P. Dessauw, P. Baldet, J. Sany, and C. Alexandre, Recruitment of new osteoblast and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma, J. Clin. Invest., 88(1): 62–66, 1991.
   Google Scholar
• A. Vacca, D. Ribatti, L. Roncali, G. Serio, F. Silvestris, and F. Dammaco, Bone marrow angiogenesis and progression in multiple myeloma, Br. J. Haematol., 87(3): 503–508, 1994.
   PubMed Web of Science ®Google Scholar
• S. Yaccoby, M.J. Wezeman, A. Henderson, M. Cottler-Fox, Q. Yi, B. Barlogie, and J. Epstein, Cancer and the microenvironment: Myeloma osteoclast interaction as a model, Cancer Res., 64(4): 2016–2023, 2004.
   Google Scholar
• I. Grigorieva, X. Thomas, and J. Epstein, The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone, Exp. Hematol., 26(7): 597–603, 1998.
   PubMed Web of Science ®Google Scholar
• J. Hardin, S. MacLeod, I. Grigorieva, R. Chang, B. Barlogie, H. Xiao, and J. Epstein, IL-6 prevents dexamethasone-induced myeloma cell death, Blood, 84(9): 3063–3070, 1994.
   Google Scholar
• A. Lichtenstein, Y. Tu, C. Fady, R. Vescio, and J. Berenson, IL-6 inhibits Fas-induced apoptosis of malignant plasma cells, Cell. Immunol., 162(2): 248–255, 1995.
   PubMed Web of Science ®Google Scholar
• Y. Ge, F. Zhan, B. Barlogie, J. Epstein, J. Shaugnessy Jr, and S. Yaccoby, Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival, Br. J. Haematol., 133(1): 83–92, 2006.
   Google Scholar
• X. Xin, T.J. Abrams, P.W. Hollenbeck, K.G. Rendhal, Y. Tang, Y.A. Oei, M.G. Embry, D.E. Swinarski, E.N. Garrett, N.K. Pryer, S. Trudel, B. Jallal, D.B. Mendel, and C.C. Heise, CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice, Clin. Cancer Res., 12(16): 4908–4915, 2006.
   Google Scholar
• P.L. Bergsagel and W.M. Kuhel, Chromosome translocations in multiple myeloma, Oncogene, 20(40): 5611–5622, 2001.
   PubMed Web of Science ®Google Scholar
• M. Chesi, E. Nardini, R.S. Lim, K.D. Smith, W.M. Kuehl, and P.L. Bergsagel, The t(4;14) translocation in myeloma deregulates both FGFR3 and a novel gene MMSET, resulting in IgH/MMSEThybrid transcripts, Blood, 92(9): 3025–3034, 1998.
   PubMed Web of Science ®Google Scholar
• M. Chesi, L.A. Brents, S.A. Ely, C. Bais, D.F. Robbiani, E.A. Mesri, W.M. Kuehl, and P.L. Bergsagel, Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma, Blood, 97(3): 729–736, 2001.
   PubMed Web of Science ®Google Scholar
• Z. Li, Y.X. Zhu, E.E. Plowright, P.L. Bergsagel, M. Chesi, B. Patterson, T.S. Hawley, R.G. Hawley, and A.K. Stewart, The myeloma associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells, Blood, 97(8): 2413–2419, 2001.
   Google Scholar
• S. Trudel, S. Ely, Y. Farooqi, M. Affer, D.F. Robbiani, M. Chesi, and P.L. Bergsagel, Inhibition of FGFR3 induces terminal differentiation and apoptosis in t(4:14) myeloma, Blood, 103: 3521–3528, 2004.
   PubMed Web of Science ®Google Scholar
• W. Matsui, C.A. Huff, Q. Wang, M.T. Malehorn, J. Barber, Y. Tanhehco, B.D. Smith, C.I. Civin, and R.J. Jones, Characterization of clonogenic multiple myeloma cells, Blood, 103(6): 2332–2336, 2004.
   PubMed Web of Science ®Google Scholar
• C. Carlo-Stella, A. Guidetti, M. Di Nicola, P. Longoni, L. Cleris, C. Lavazza, M. Milanesi, R. Milani, M. Carabba, L. Farina, F. Formelli, A.M. Gianni, and P. Corradini, CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice, Exp. Haematol., 34(6): 721–727, 2006.
   Google Scholar
• M. Attal and J.L. Harousseau, Autologous peripheral blood progenitor cell transplantation for multiple myeloma, Bailieres Best Pract. Res. Clin. Haematol., 12(1-2): 171–191, 1999.
   Google Scholar
• J.A. Cild, G.J. Morgan, F.E. Davies, R.G. Owen, S.E. Bell, K. Hawkins, J. Brown, M.T. Drayson, and P.J. Selby, High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma, N. Eng. J. Med., 348(19): 1875–1883,2003.
   Google Scholar
• S.J. Harrison and G. Cook, Immunotherapy in multiple Myeloma – possibility or probability? Br. J. Haematol., 130(3): 344–362, 2005.
   Google Scholar
• L.A. Emens, Roadmap to a better therapeutic tumor vaccine, Int. Rev. Immunol., 25(5-6): 415–443, 2006.
   Web of Science ®Google Scholar
• L.F. Porrata, D.A. Gastineau, D. Padley, K. Bundy, and S.N. Markovic, Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cells tranplantation, Leuk. Lymphoma, 44(6): 997–1000, 2003.
   PubMed Web of Science ®Google Scholar
• D.M. Andrews, A.A. Scalzo, W.M. Yokoyama, M.J. Smyth, and M.A. Degli-Espositi, Functional interactions between dendritic cells and NK cells during viral infection, Nat. Immunol., 4(2): 175–181, 2003.
   Google Scholar
• D.H. Chang, N. Liu, V. Klimek, H. Hassoun, A. Mazumder, S.D. Nimer, S. Jagannath, and M.V. Dhodapkar, Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: Therapeutic implications, Blood, 108(2): 618–621, 2006.
   PubMed Web of Science ®Google Scholar
• A. Villunger, A. Egle, I. Marshitz, M. Kos, G. Bock, H. Ludwig, S. Geley, R. Kofler, and R. Greil, Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor induced suppression of immune surveillance, Blood, 90(1): 12–20, 1997.
   Google Scholar
• T. Oyama, S. Ran, T. Ishida, S. Nadaf, L. Kerr, D.P. Carbone, and D.I. Gabrilovich, Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-K B activation in hemopoietic progenitor cells, J. Immunol., 160(3): 1224–1232, 1998.
   PubMed Web of Science ®Google Scholar
• B. Agrawal, M.J. Krantz, M.A. Reddish, and B.M. Longenecker, Cancer associated MUC1 mucin inhibits human T cell proliferation, which is reversible by IL-2, Nat. Med., 4(1): 43–49, 1998.
   PubMed Web of Science ®Google Scholar
• J.H. Harrison, G. Cook, R.J.B. Nibbs, and M. Prince, Immunotherapy of multiple myeloma: The start of a long and tortuous journey, Expert Rev. Anticancer Ther., 6(12): 1769–1785, 2006.
   Web of Science ®Google Scholar
• Q. Yi, A. Osterborg, S. Bergenbrant, H. Mellstedt, G. Holm, and A.K. Lefvert, Idiotype-reactive T cell subsets and tumor load in monoclonal gammopathies, Blood, 86(8): 3043–3049, 1995.
   PubMed Web of Science ®Google Scholar
• Y.J. Wen, B. Barlogie, and Q. Yi, Idiotype-specific cytotoxic T lymphocytes in multiple Myeloma: evidence for their capacity to lyse autologous primary tumor cells, Blood, 97(6): 1750–1755, 2001.
   PubMed Web of Science ®Google Scholar
• Y. Li, M. Benandi, Y. Deng, C. Dunbar, N. Munshi, S. Jagannath, L.W. Kwak, and H.K. Lyerly, Tumor specific recognition of human myeloma cells by idiotype induced CD8 T cells, Blood, 96(8): 2828–2833, 2000.
   Google Scholar
• C. Bertinetti, K. Zirlik, K. Heining-Mikesch, G. Ihorst, H. Dierbach, C.F. Waller, and H. Veelken, A phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression, Cancer Res., 66(8): 4496–4502, 2006.
   PubMed Web of Science ®Google Scholar
• A. Liso, K.E. Stockerl-Goldstein, S. Auffermann-Gretzinger, C.J. Benike, V. Reichardt, van A. Beckoven, R. Rajapaksa, E.G. Engelman, K.G. Blume, and R. Levy, Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma, Biol. Blood Marrow Transplant, 6(6): 621–627, 2000.
   PubMed Web of Science ®Google Scholar
• L.W. Kwak, R. Pennington, and D.L. Longo, Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumour-derived idiotype: A strategy for enhancing the specific antitumour effect of marrow grafts, Blood, 87(7): 3053–3060, 1996.
   Google Scholar
• S.B. Kim, S. Baskar, and L.W. Kwak, In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells, Leuk. Lymphoma, 44(7): 1201–1208, 2003.
   PubMed Web of Science ®Google Scholar
• T. Osada, T.M. Clay, C.Y. Woo, M.A. Morse, and H.K. Lyerly, Dendritic cell based immunotherapy, Int. Rev. Immunol., 25(5-6): 377–413, 2006.
   Web of Science ®Google Scholar
• P. Serafini, K. Meckel, M. Kelso, K. Noonan, J. Califano, W. Koch, L. Dolcetti, V. Bronte, and I. Borrello, Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function, J. Exp. Med., 203(12): 2691–702, 2006.
   PubMed Web of Science ®Google Scholar
• V. Reichardt, C. Okada, A. Liso, C. Benike, K. Stockerl-Goldstein, E. Engleman, K. Blume, and R. Levy, Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma – a feasibility study, Blood, 93(7): 2411–2419, 1999.
   PubMed Web of Science ®Google Scholar
• V.L. Reichardt, C. Milazzo, W. Brugger, H. Einsele, L. Kanz, and P. Brossart, Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells, Haematologica, 88(10): 1139–1149, 2003.
   PubMed Web of Science ®Google Scholar
• Q. Yi, Immunotherapy in multiple myeloma: current strategies and future prospects, Expert Rev Vaccines, 2(3): 391–398, Jun., 2003.
   PubMedGoogle Scholar
• Q. Yi, Dendritic cell-based immunotherapy in multiple myeloma, Leuk Lymphoma, 44(12): 2031–2038, Dec., 2003.
   PubMed Web of Science ®Google Scholar
• S.M. Szmania, N.A. Rosen, J. Freeman, R.B. Batchu, B. Barlogie, G. Tricot, M.H. Cottler-Fox, Q. Yi, and F. Van Rhee, Cryopreserved tumor protein loaded dendritic cell vaccines induce potent immune responses in patient with poor prognosis multiple myeloma, Blood, 102: 90–91, abstract no. 1652, 2003.
   Google Scholar
• A.E. Guardino, R. Rajapaksa, K.H. Ong, K. Sheehan, and R. Levy, Production of myeloid dendritic cells (DCs) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma, Cytotherapy, 8(3): 277–289, 2006.
   PubMed Web of Science ®Google Scholar
• K. Noonan, W. Matsui, P. Serafini, R. Carbley, G. Tan, J. Khalili, M. Bonyhadi, H. Levitsky, K. Whartenby, and I. Borrello, Activated marrow infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors, Cancer Res., 65(5): 2026–2034, 2005.
   Google Scholar
• S. Chen, C. Zani, Y. Khouri, and W.A. Marasco, Design of a genetic immunotoxin to eliminate toxin immunogenicity, Gene. Ther., 2(2): 116–123, 1995.
   Google Scholar
• J.H. Ellis, K.A. Barber, A. Tutt, C. Hale, A.P. Lewis, M.J. Glennie, G.T. Stevenson, and J.S. Crowe, Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma, J. Immunol., 155(2): 925–937, 1995.
   PubMed Web of Science ®Google Scholar
• I.B. Bayer-Garner, R.D. Sanderson, M.V. Dhodapkar, R.B. Owens, and C.S. Wilson, Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions, Mod. Pathol., 14(10): 1052–1058, 2001.
   PubMed Web of Science ®Google Scholar
• Y.W. Huang, J.A. Richardson, and E.S. Vitetta, Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells, Cancer Res., 55(3): 610–16, 1995.
   PubMed Web of Science ®Google Scholar
• J.J. Westendorf, G.J. Ahmann, R.J. Armitage, M.K. Spriggs, J. Lust, P.R. Greipp, J.A. Katzmann, and D.F. Jelinek, CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line, J. Immunol., 152(1): 117–128, 1994.
   Google Scholar
• J.C. Yang, L. Haworth, R.M. Sherry, P. Hwu, D.J. Schwarzentruber, S.L. Topalian, S.M. Steinberg, H.X. Chen, and S.A. Rosenberg, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, N. Engl. J. Med., 349(5): 427–434, 2003.
   PubMed Web of Science ®Google Scholar
• S.H. Lim, Y. Zhang, Z. Wang, R. Varadarajan, P. Periman, and W.V. Esler, Rituximab administration following autologous stem cells transplantation for multiple myeloma is associated with severe IgM deficiency, Blood, 103(5): 1971–1972, 2004.
   Google Scholar
• P. Musto, A.M. Carella, Jr. M.M. Greco, A. Falcone, G. Sanpaolo, C. Bodenizza, N. Cascavilla, L. Melillo, and A.M. Carella, Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation, Br. J. Haematol., 123(4): 746–747, 2003.
   PubMed Web of Science ®Google Scholar
• W. Matsui, C.A. Huff, Q. Wang, M.T. Malehorn, J. Barber, Y. Tanhehco, B.D. Smith, C.I. Civin, and R.J. Jones, Characterization of clonogenic multiple myeloma cells, Blood, 103(6): 2332–2336, 2004.
   PubMed Web of Science ®Google Scholar
• R.J. Jones, Differentiation of cancer stem cells, Exp. Hematol., 31(7 Suppl. 1), S136, 2003.
   Google Scholar
• T. Azuma, K. Otsuki, C.J. Kuzushima, C.J. Froelich, S. Fujita, and M. Yasukawa, Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes, Clin. Cancer Res., 10(21): 7402–7412, 2004.
   Google Scholar
• T. Goto, S.J. Kennel, M. Abe, M. Takishita, M. Kosaka, A. Solomon, and S. Saito, A novel membrane antigen selectively expressed on terminally differentiated human B cells, Blood, 84(6): 1922–1930, 1994.
   PubMed Web of Science ®Google Scholar
• A. Jalili, S. Ozaki, T. Hara, H. Shibata, T. Hashimoto, M. Abe, Y. Nishioka, and T. Matsumoto, Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma, Blood, 106(10): 3538–3545, 2005.
   Google Scholar
• M. Chiriva-Internati, Y. Liu, J.A. Weidanz, F. Grizzi, H. You, W. Zhou, K. Bumm, B. Barlogie, J.L. Mehta, and P.L. Hermonat, Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24, Blood, 102(9): 3100–3107, 2003.
   Google Scholar
• S.B. Rew, K. Peggs, I. Sanjuan, A.R. Pizzey, Y. Koishihara, S. Kawai, M. Kosaka, S. Ozaki, B. Chain, and K.L. Yong, Generation of potent antitumour CTL from patients with multiple myeloma directed against HM1.24, Clin. Cancer Res., 11(9): 3377–3384, 2005.
   Google Scholar
• C. Rosenfeld, M.A. Cheever, and A. Gaiger, WT1 in acute leukaemia, chronic myelogenous leukaemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies, Leukaemia, 17(7): 1301–1312, 2003.
   Google Scholar
• C. Scheibenbogen, A. Letsch, E. Thiel, A. Schmittel, V. Mailaender, S. Baerwolf, D. Nagorsen, and U. Keilholz. CD8 T-cell responses to Wilms tumour gene product WT1 and proteinase 3 in patients with acute myeloid leukaemia, Blood, 100(6): 2132–2137, 2002.
   Google Scholar
• C. Choi, M. Witzens, M. Bucur, M. Feuerer, N. Sommerfeldt, A. Trojan, A. Ho, V. Schmirrmacher, H. Goldschmidt, and P. Beckove, Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma, Blood, 105(5): 2132–2134, 2005.
   Google Scholar
• D. Atanackovic, J. Arfsten, Y. Cao, S. Gnjatic, F. Schnieders, K. Bartels, G. Schilling, C. Faltz, C. Wolschke, J. Dierlamm, G. Ritter, T. Eiermann, D.K. Hossfeld, A.R. Zander, A.A. Jungbluth, L.J. Old, C. Bokemeyer, and N. Kroger, Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation, Blood, 109(3): 1103–1112, 2007.
   PubMed Web of Science ®Google Scholar
• F. Van Rhee, S.M. Szmania, F. Zhan, S.K. Gupta, M. Pomtree, P. Lin, R.B. Batchu, A. Moreno, G. Spagnoli, J. Shaughnessy, and G. Tricot, NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses, Blood, 105(10): 3939–3944, 2005.
   PubMed Web of Science ®Google Scholar
• M. Chiriva Internati, Z. Wang, E. Salati, D. Wroblewski, and S.H. Lim, Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma, Scand. J. Immunol., s56(4): 429–433, 2002.
   Google Scholar
• R.A. Morgan, M.E. Dudley, J.R. Wunderlich, M.S. Hughes, J.C. Yang, R.M. Sherry, R.E. Royal, S.L. Topalian, U.S. Kammula, N.P. Restifo, Z. Zheng, A. Nahvi, C.R. de Vries, L.J. Rogers-Freezer, S.A. Mavroukakis, and S.A. Rosenberg, Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, 314(5796): 126–129, 2006.
   PubMed Web of Science ®Google Scholar
• D.I. Gabrilovich, V. Bronte, S.H. Chen, M.P. Colombo, A. Ochoa, S. Ostrand-Rosenberg, and H. Schreiber, The terminology issue for myeloid-derived suppressor cells, Cancer Res., 67(1): 425, 2007.
   PubMed Web of Science ®Google Scholar
• I.M. Borrello and E.M. Sotomayor, Cancer vaccines for hematologic malignancies, Cancer Control, 9(2): 138–151, 2002.
   Google Scholar
• G.A. Rabinovich, D. Gabrilovich, and E.M. Sotomayor, Immunosuppressive strategies that are mediated by tumor cells, Annu. Rev. Immunol., 25: 267–296, 2006.
   Google Scholar